Short Interest in Evaxion Biotech A/S (NASDAQ:EVAX) Decreases By 22.0%

by · The Cerbat Gem

Evaxion Biotech A/S (NASDAQ:EVAX – Get Free Report) was the recipient of a significant drop in short interest in October. As of October 31st, there was short interest totalling 52,600 shares, a drop of 22.0% from the October 15th total of 67,400 shares. Based on an average daily volume of 47,600 shares, the short-interest ratio is currently 1.1 days.

Hedge Funds Weigh In On Evaxion Biotech A/S

An institutional investor recently bought a new stake in Evaxion Biotech A/S stock. Invst LLC acquired a new position in Evaxion Biotech A/S (NASDAQ:EVAX – Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 54,000 shares of the company’s stock, valued at approximately $156,000. Invst LLC owned about 1.00% of Evaxion Biotech A/S as of its most recent filing with the Securities and Exchange Commission. 11.04% of the stock is owned by institutional investors.

Evaxion Biotech A/S Price Performance

NASDAQ:EVAX traded down $0.24 during mid-day trading on Friday, hitting $1.44. 76,290 shares of the stock traded hands, compared to its average volume of 28,397. The company has a debt-to-equity ratio of 7.99, a current ratio of 1.00 and a quick ratio of 2.80. Evaxion Biotech A/S has a 12-month low of $1.40 and a 12-month high of $13.61. The business’s 50-day moving average price is $2.77 and its 200 day moving average price is $3.06.

Evaxion Biotech A/S (NASDAQ:EVAX – Get Free Report) last released its quarterly earnings results on Thursday, October 31st. The company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.08. The company had revenue of $3.02 million during the quarter, compared to analysts’ expectations of $0.19 million. Research analysts predict that Evaxion Biotech A/S will post -0.15 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and set a $14.00 price objective on shares of Evaxion Biotech A/S in a research note on Friday, November 1st.

Check Out Our Latest Stock Analysis on Evaxion Biotech A/S

Evaxion Biotech A/S Company Profile

(Get Free Report)

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.

Recommended Stories